Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial
© 2014 S. Karger AG, Basel..
BACKGROUND AND PURPOSE: WARCEF randomized 2,305 patients in sinus rhythm with ejection fraction (EF) ≤ 35% to warfarin (INR 2.0-3.5) or aspirin 325 mg. Warfarin reduced the incident ischemic stroke (IIS) hazard rate by 48% over aspirin in a secondary analysis. The IIS rate in heart failure (HF) is too low to warrant routine anticoagulation but epidemiologic studies show that prior stroke increases the stroke risk in HF. In this study, we explore IIS rates in WARCEF patients with and without baseline stroke to look for risk factors for IIS and determine if a subgroup with an IIS rate high enough to give a clinically relevant stroke risk reduction can be identified.
METHODS: We compared potential stroke risk factors between patients with baseline stroke and those without using the exact conditional score test for Poisson variables. We looked for risk factors for IIS, by comparing IIS rates between different risk factors. For EF we tried cut-off points of 10, 15 and 20%. The cut-off point 15% was used as it was the highest EF that was associated with a significant increase in IIS rate. IIS and EF strata were balanced as to warfarin/aspirin assignment by the stratified randomized design. A multiple Poisson regression examined the simultaneous effects of all risk factors on IIS rate. IIS rates per hundred patient years (/100 PY) were calculated in patient groups with significant risk factors. Missing values were assigned the modal value.
RESULTS: Twenty of 248 (8.1%) patients with baseline stroke and 64 of 2,048 (3.1%) without had IIS. IIS rate in patients with baseline stroke (2.37/100 PY) was greater than patients without (0.89/100 PY) (rate ratio 2.68, p < 0.001). Fourteen of 219 (6.4%) patients with ejection fraction (EF) <15% and 70 of 2,079 (3.4%) with EF ≥ 15% had IIS. In the multiple regression analysis stroke at baseline (p < 0.001) and EF <15% vs. ≥ 15% (p = 0.005) remained significant predictors of IIS. IIS rate was 2.04/100 PY in patients with EF <15% and 0.95/100 PY in patients with EF ≥ 15% (p = 0.009). IIS rate in patients with baseline stroke and reduced EF was 5.88/100 PY with EF <15% decreasing to 2.62/100 PY with EF <30%.
CONCLUSIONS: In a WARCEF exploratory analysis, prior stroke and EF <15% were risk factors for IIS. Further research is needed to determine if a clinically relevant stroke risk reduction is obtainable with warfarin in HF patients with prior stroke and reduced EF.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Cerebrovascular diseases (Basel, Switzerland) - 38(2014), 3 vom: 08., Seite 176-81 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pullicino, Patrick M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5Q7ZVV76EI |
|---|
| Anmerkungen: |
Date Completed 10.07.2015 Date Revised 21.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1159/000365502 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM242643450 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM242643450 | ||
| 003 | DE-627 | ||
| 005 | 20231224130834.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000365502 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0808.xml |
| 035 | |a (DE-627)NLM242643450 | ||
| 035 | |a (NLM)25300706 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pullicino, Patrick M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.07.2015 | ||
| 500 | |a Date Revised 21.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2014 S. Karger AG, Basel. | ||
| 520 | |a BACKGROUND AND PURPOSE: WARCEF randomized 2,305 patients in sinus rhythm with ejection fraction (EF) ≤ 35% to warfarin (INR 2.0-3.5) or aspirin 325 mg. Warfarin reduced the incident ischemic stroke (IIS) hazard rate by 48% over aspirin in a secondary analysis. The IIS rate in heart failure (HF) is too low to warrant routine anticoagulation but epidemiologic studies show that prior stroke increases the stroke risk in HF. In this study, we explore IIS rates in WARCEF patients with and without baseline stroke to look for risk factors for IIS and determine if a subgroup with an IIS rate high enough to give a clinically relevant stroke risk reduction can be identified | ||
| 520 | |a METHODS: We compared potential stroke risk factors between patients with baseline stroke and those without using the exact conditional score test for Poisson variables. We looked for risk factors for IIS, by comparing IIS rates between different risk factors. For EF we tried cut-off points of 10, 15 and 20%. The cut-off point 15% was used as it was the highest EF that was associated with a significant increase in IIS rate. IIS and EF strata were balanced as to warfarin/aspirin assignment by the stratified randomized design. A multiple Poisson regression examined the simultaneous effects of all risk factors on IIS rate. IIS rates per hundred patient years (/100 PY) were calculated in patient groups with significant risk factors. Missing values were assigned the modal value | ||
| 520 | |a RESULTS: Twenty of 248 (8.1%) patients with baseline stroke and 64 of 2,048 (3.1%) without had IIS. IIS rate in patients with baseline stroke (2.37/100 PY) was greater than patients without (0.89/100 PY) (rate ratio 2.68, p < 0.001). Fourteen of 219 (6.4%) patients with ejection fraction (EF) <15% and 70 of 2,079 (3.4%) with EF ≥ 15% had IIS. In the multiple regression analysis stroke at baseline (p < 0.001) and EF <15% vs. ≥ 15% (p = 0.005) remained significant predictors of IIS. IIS rate was 2.04/100 PY in patients with EF <15% and 0.95/100 PY in patients with EF ≥ 15% (p = 0.009). IIS rate in patients with baseline stroke and reduced EF was 5.88/100 PY with EF <15% decreasing to 2.62/100 PY with EF <30% | ||
| 520 | |a CONCLUSIONS: In a WARCEF exploratory analysis, prior stroke and EF <15% were risk factors for IIS. Further research is needed to determine if a clinically relevant stroke risk reduction is obtainable with warfarin in HF patients with prior stroke and reduced EF | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Warfarin |2 NLM | |
| 650 | 7 | |a 5Q7ZVV76EI |2 NLM | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 700 | 1 | |a Qian, Min |e verfasserin |4 aut | |
| 700 | 1 | |a Sacco, Ralph L |e verfasserin |4 aut | |
| 700 | 1 | |a Freudenberger, Ron |e verfasserin |4 aut | |
| 700 | 1 | |a Graham, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Teerlink, John R |e verfasserin |4 aut | |
| 700 | 1 | |a Mann, Douglas |e verfasserin |4 aut | |
| 700 | 1 | |a Di Tullio, Marco R |e verfasserin |4 aut | |
| 700 | 1 | |a Ponikowski, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Lok, Dirk J |e verfasserin |4 aut | |
| 700 | 1 | |a Anker, Stefan D |e verfasserin |4 aut | |
| 700 | 1 | |a Lip, Gregory Y H |e verfasserin |4 aut | |
| 700 | 1 | |a Estol, Conrado J |e verfasserin |4 aut | |
| 700 | 1 | |a Levin, Bruce |e verfasserin |4 aut | |
| 700 | 1 | |a Mohr, Jay P |e verfasserin |4 aut | |
| 700 | 1 | |a Thompson, John L P |e verfasserin |4 aut | |
| 700 | 1 | |a Homma, Shunichi |e verfasserin |4 aut | |
| 700 | 0 | |a WARCEF Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Homma, S |e investigator |4 oth | |
| 700 | 1 | |a Thompson, J L P |e investigator |4 oth | |
| 700 | 1 | |a Pullicino, P |e investigator |4 oth | |
| 700 | 1 | |a Freudenberger, R |e investigator |4 oth | |
| 700 | 1 | |a Graham, S |e investigator |4 oth | |
| 700 | 1 | |a Teerlink, J |e investigator |4 oth | |
| 700 | 1 | |a Ammon, S |e investigator |4 oth | |
| 700 | 1 | |a Mann, D |e investigator |4 oth | |
| 700 | 1 | |a Mohr, J P |e investigator |4 oth | |
| 700 | 1 | |a Sacco, R L |e investigator |4 oth | |
| 700 | 1 | |a Massie, B |e investigator |4 oth | |
| 700 | 1 | |a Anker, S |e investigator |4 oth | |
| 700 | 1 | |a Labovitz, A |e investigator |4 oth | |
| 700 | 1 | |a Moy, C |e investigator |4 oth | |
| 700 | 1 | |a Moy, C |e investigator |4 oth | |
| 700 | 1 | |a Gilbert, P |e investigator |4 oth | |
| 700 | 1 | |a Gutmann, L |e investigator |4 oth | |
| 700 | 1 | |a Marler, J |e investigator |4 oth | |
| 700 | 1 | |a Homma, S |e investigator |4 oth | |
| 700 | 1 | |a Mejia, V |e investigator |4 oth | |
| 700 | 1 | |a Gabriel, A |e investigator |4 oth | |
| 700 | 1 | |a Borden, S |e investigator |4 oth | |
| 700 | 1 | |a Peña, E |e investigator |4 oth | |
| 700 | 1 | |a Harris, C |e investigator |4 oth | |
| 700 | 1 | |a Khadouri, R |e investigator |4 oth | |
| 700 | 1 | |a Gohs, D |e investigator |4 oth | |
| 700 | 1 | |a Brown, M |e investigator |4 oth | |
| 700 | 1 | |a Berry, G |e investigator |4 oth | |
| 700 | 1 | |a Disantis, D |e investigator |4 oth | |
| 700 | 1 | |a Scullin, M |e investigator |4 oth | |
| 700 | 1 | |a Smith, P |e investigator |4 oth | |
| 700 | 1 | |a Kohsaka, S |e investigator |4 oth | |
| 700 | 1 | |a Watson, W |e investigator |4 oth | |
| 700 | 1 | |a Guillory, L |e investigator |4 oth | |
| 700 | 1 | |a Thompson, J L P |e investigator |4 oth | |
| 700 | 1 | |a Levin, B |e investigator |4 oth | |
| 700 | 1 | |a Buchsbaum, R |e investigator |4 oth | |
| 700 | 1 | |a Del Valle, M |e investigator |4 oth | |
| 700 | 1 | |a Sanford, A |e investigator |4 oth | |
| 700 | 1 | |a Levy, G |e investigator |4 oth | |
| 700 | 1 | |a Tea, K |e investigator |4 oth | |
| 700 | 1 | |a Grier, J |e investigator |4 oth | |
| 700 | 1 | |a Swydan, L |e investigator |4 oth | |
| 700 | 1 | |a O'Hare, B |e investigator |4 oth | |
| 700 | 1 | |a Prodhan, R |e investigator |4 oth | |
| 700 | 1 | |a Arbing, R |e investigator |4 oth | |
| 700 | 1 | |a Flanagan, E |e investigator |4 oth | |
| 700 | 1 | |a Duverger, E |e investigator |4 oth | |
| 700 | 1 | |a Peljto, A |e investigator |4 oth | |
| 700 | 1 | |a Lo, W |e investigator |4 oth | |
| 700 | 1 | |a Tierney, A |e investigator |4 oth | |
| 700 | 1 | |a Henriquez, A |e investigator |4 oth | |
| 700 | 1 | |a Keen, J |e investigator |4 oth | |
| 700 | 1 | |a del Zoppo, G J |e investigator |4 oth | |
| 700 | 1 | |a Albers, G W |e investigator |4 oth | |
| 700 | 1 | |a Eliasziw, M |e investigator |4 oth | |
| 700 | 1 | |a Hinchey, J A |e investigator |4 oth | |
| 700 | 1 | |a Johnston, K C |e investigator |4 oth | |
| 700 | 1 | |a Lowe, A M |e investigator |4 oth | |
| 700 | 1 | |a Piña, I L |e investigator |4 oth | |
| 700 | 1 | |a Swain, J A |e investigator |4 oth | |
| 700 | 1 | |a Teerlink, J R |e investigator |4 oth | |
| 700 | 1 | |a Ammon, S |e investigator |4 oth | |
| 700 | 1 | |a Slomiak, S |e investigator |4 oth | |
| 700 | 1 | |a Cape, L |e investigator |4 oth | |
| 700 | 1 | |a Barnett, H J M |e investigator |4 oth | |
| 700 | 1 | |a Bruno, A |e investigator |4 oth | |
| 700 | 1 | |a Easton, J D |e investigator |4 oth | |
| 700 | 1 | |a Levine, S |e investigator |4 oth | |
| 700 | 1 | |a Sahlas, D |e investigator |4 oth | |
| 700 | 1 | |a Bleyer, F |e investigator |4 oth | |
| 700 | 1 | |a Carson, P |e investigator |4 oth | |
| 700 | 1 | |a Ellis, A |e investigator |4 oth | |
| 700 | 1 | |a Miller, A |e investigator |4 oth | |
| 700 | 1 | |a Palmeri, S T |e investigator |4 oth | |
| 700 | 1 | |a Labovitz, A |e investigator |4 oth | |
| 700 | 1 | |a Di Tullio, M |e investigator |4 oth | |
| 700 | 1 | |a Bierig, M |e investigator |4 oth | |
| 700 | 1 | |a Liu, R |e investigator |4 oth | |
| 700 | 1 | |a Donato, C |e investigator |4 oth | |
| 700 | 1 | |a Hart, R |e investigator |4 oth | |
| 700 | 1 | |a McKay, C |e investigator |4 oth | |
| 700 | 1 | |a Wilson, L |e investigator |4 oth | |
| 700 | 1 | |a Frey, E |e investigator |4 oth | |
| 700 | 1 | |a Hayward, K |e investigator |4 oth | |
| 700 | 1 | |a Stein-Beal, P |e investigator |4 oth | |
| 700 | 1 | |a Konczarek, L |e investigator |4 oth | |
| 700 | 1 | |a Diek, M |e investigator |4 oth | |
| 700 | 1 | |a Rohwedder, M |e investigator |4 oth | |
| 700 | 1 | |a Bohdanowicz-Zazula, M |e investigator |4 oth | |
| 700 | 1 | |a Peerenboom-Fey, C F |e investigator |4 oth | |
| 700 | 1 | |a Vissiennon, M |e investigator |4 oth | |
| 700 | 1 | |a Rex, G |e investigator |4 oth | |
| 700 | 1 | |a Varga, M |e investigator |4 oth | |
| 700 | 1 | |a Kovtun, O |e investigator |4 oth | |
| 700 | 1 | |a Orlyk, V |e investigator |4 oth | |
| 700 | 1 | |a Arenberger, P |e investigator |4 oth | |
| 700 | 1 | |a Jaros, J |e investigator |4 oth | |
| 700 | 1 | |a Ruiz, A |e investigator |4 oth | |
| 700 | 1 | |a Zimmermann, M |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Cerebrovascular diseases (Basel, Switzerland) |d 1997 |g 38(2014), 3 vom: 08., Seite 176-81 |w (DE-627)NLM090577663 |x 1421-9786 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2014 |g number:3 |g day:08 |g pages:176-81 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000365502 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2014 |e 3 |b 08 |h 176-81 | ||